secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000784199-23-000146
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q3 revenue $87.9M (+14% YoY); raises FY2023 revenue and EBITDA guidance
--------------------------------------------------------------------------------

- Revenue $87.9M, up 14% GAAP and 12% constant currency vs Q3 2022; net loss ($9.8M) or ($0.24)/share.
- Non-GAAP net income $749k ($0.02/share) vs ($1.9M) loss a year ago; adjusted EBITDA up 34% to $13.9M.
- Aortic stent graft revenue surged 30% GAAP (22% constant currency); On-X revenue up 14% (13% cc).
- FY2023 revenue guidance raised to $349-351M (prior $342-350M); constant currency growth now 11-12%.
- Expects 2023 adjusted EBITDA >$52M (+25% YoY); PERSEVERE trial enrollment nearing completion (90 of 93).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419923000146/0000784199-23-000146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419923000146/aort-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000784199-23-000146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer